U.S. patent application number 09/800179 was filed with the patent office on 2001-10-11 for substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives.
Invention is credited to Selliah, Robert D..
Application Number | 20010029265 09/800179 |
Document ID | / |
Family ID | 21740176 |
Filed Date | 2001-10-11 |
United States Patent
Application |
20010029265 |
Kind Code |
A1 |
Selliah, Robert D. |
October 11, 2001 |
Substituted tetrahydrofuran analogs of prostaglandins as ocular
hypotensives
Abstract
Substituted tetrahydrofuran analogs of prostaglandins and
methods of their use in treating glaucoma and ocular hypertension
are disclosed.
Inventors: |
Selliah, Robert D.; (Fort
Worth, TX) |
Correspondence
Address: |
ALCON RESEARCH, LTD.
R&D COUNSEL, Q-148
6201 SOUTH FREEWAY
FORT WORTH
TX
76134-2099
US
|
Family ID: |
21740176 |
Appl. No.: |
09/800179 |
Filed: |
March 6, 2001 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09800179 |
Mar 6, 2001 |
|
|
|
09440248 |
Nov 15, 1999 |
|
|
|
6197812 |
|
|
|
|
09440248 |
Nov 15, 1999 |
|
|
|
08809920 |
Apr 4, 1997 |
|
|
|
5994397 |
|
|
|
|
08809920 |
Apr 4, 1997 |
|
|
|
PCT/US96/17900 |
Nov 12, 1996 |
|
|
|
60009866 |
Dec 22, 1995 |
|
|
|
Current U.S.
Class: |
514/473 ;
549/478 |
Current CPC
Class: |
A61P 27/06 20180101;
C07D 493/04 20130101; C07D 307/18 20130101; A61K 31/5585 20130101;
A61P 43/00 20180101; C07D 307/20 20130101; A61P 27/02 20180101 |
Class at
Publication: |
514/473 ;
549/478 |
International
Class: |
A61K 031/341; C07D
307/02 |
Claims
What is claimed is:
1. A method of treating glaucoma or ocular hypertension in a
patient, which comprises administering to the patient a
pharmaceutically effective amount of a compound of formula (III):
17wherein: R=ophthalmically acceptable ester moiety,
CO.sub.2R.sup.1, CONR.sup.7R.sup.8, CH.sub.2OR.sup.9, or
CH.sub.2NR.sup.10R.sup.11 where R.sup.1=H or cationic salt moiety;
R.sup.7 and R.sup.8 are the same or different=H or alkyl;
R.sup.9=H, acyl, or alkyl; R.sup.10 and R.sup.11 are the same or
different=H, acyl, or alkyl; with the proviso that if one of
R.sup.10 and R.sup.11=acyl, then the other=H or alkyl; n=0, 2;
18wherein: Z=C.ident.C, trans CH.dbd.CH or CH.sub.2CH.sub.2;
Y.sup.2=halogen or alkoxy; X.sup.2=O, S, or CH.sub.2; and A=cis
CH.dbd.CH, CH.sub.2CH.sub.2, or C.ident.C; R.sup.2, R.sup.3 are
different=H and OH; and R.sup.4=cyclohexyl or linear or branched
C.sub.5-C.sub.7 alkyl.
2. The method of claim 1, where the compound is administered
topically.
3. The method of claim 2, wherein the compound is administered as a
solution, suspension, or emulsion.
4. The method of claim 2, wherein G is (i).
5. The method of claim 2, wherein G is (ii).
6. The method of claim 4, wherein R is an ophthalmically acceptable
ester selected from the group consisting of: isopropyl and
neopentyl esters of carboxylic acids.
7. The method of claim 5, wherein R is an ophthalmically acceptable
ester selected from the group consisting of: isopropyl and
neopentyl esters of carboxylic acids, and R.sup.4 is
cyclohexyl.
8. The method of claim 3, wherein the concentration of the compound
is between about 0.00003 to about 0.5 weight percent.
9. The method of claim 8, wherein the concentration of the compound
is between about 0.0005 to about 0.03 weight percent.
10. The method of claim 9, wherein the concentration of the
compound is between about 0.001 and about 0.01 weight percent.
11. A compound of formula (III): 19wherein: R=a pharmaceutically
acceptable ester moiety, CO.sub.2R.sup.1, CONR.sup.7R.sup.8,
CH.sub.2OR.sup.9, or CH.sub.2NR.sup.10OR.sup.11, wherein R.sup.1=H
or cationic salt moiety; R.sup.7 and R.sup.8 are the same or
different=H or alkyl; R.sup.9=H, acyl, or alkyl; R.sup.10 and
R.sup.11 are the same or different=H, acyl, or alkyl; with the
proviso that if one of R.sup.10 and R.sup.11=acyl, then the other=H
or alkyl; n=0, 2; G is: 20wherein: Z=C.ident.C, trans CH.dbd.CH or
CH.sub.2CH.sub.2; Y.sup.2=halogen or alkoxy; X.sup.2=O, S, or
CH.sub.2; and A=cis CH.dbd.CH, CH.sub.2CH.sub.2, or C.ident.C;
R.sup.2, R.sup.3 are different=H and OH; and R.sup.4=cyclohexyl or
linear or branched C.sub.5-C.sub.7 alkyl.
12. The compound of claim 11, where G is: 21wherein: Z=trans
CH.dbd.CH; CH.sub.2CH.sub.2; or C.ident.C; Y.sup.2=halogen or
alkoxy; X.sup.2=O, S, or CH.sub.2; and A=cis CH.dbd.CH,
CH.sub.2CH.sub.2, or C.ident.C.
13. The compound of claim 12 having the following formula: 22
14. The compound of claim 12 having the following formula: 23
15. The compound of claim 11, where G is: 24wherein:
Y=CH.sub.2CH.dbd.CH (cis olefin), CH.dbd.CHCH.sub.2 (cis olefin),
or CH.sub.2CH.sub.2CH.sub.2- ; Z=trans CH.dbd.CH; CH.sub.2CH.sub.2;
C.ident.C.
16. The compound of claim 15, having the following formula: 25
17. The compound of claim 15 having the following formula: 26
18. An ophthalmic composition for the treatment of glaucoma and
ocular hypertension, comprising a compound of formula (III):
27wherein: R=ophthalmically acceptable ester moiety,
CO.sub.2R.sup.1, CONR.sup.7R.sup.8, CH.sub.2OR.sup.9, or
CH.sub.2NR.sup.10R.sup.11, where R.sup.1=H or cationic salt;
R.sup.7 and R.sup.8 are the same or different=H or alkyl;
R.sup.9=H, acyl, or alkyl; R.sup.10 and R.sup.11 are the same or
different=H, acyl, or alkyl; with the proviso that if one of
R.sup.10 and R.sup.11=acyl, then the other=H or alkyl; n=0, 2; G
is: 28wherein: Y=CH.sub.2CH.dbd.CH (cis olefin), CH.dbd.CHCH.sub.2
(cis olefin), or CH.sub.2CH.sub.2CH.sub.2; Z=trans CH.dbd.CH;
CH.sub.2CH.sub.2; C.ident.C; Y.sup.2=halogen or alkoxy; X=O, S, or
CH.sub.2; and A=cis CH.dbd.CH, CH.sub.2CH.sub.2, or C.ident.C; one
of R.sup.2 and R.sup.3=H, and the other=F or OH, where the OH may
be free or functionally modified; or R.sup.2 and R.sup.3 taken
together=OCH.sub.2CH.sub.2O or double bonded O (carbonyl); and
R.sup.4=cyclohexyl, linear or branched C.sub.5-C.sub.7 alkyl, or
R.sup.5, wherein: R.sup.5=(CH.sub.2).sub.mXphenyl or
(CH.sub.2).sub.p Z.sup.2, where X.dbd.O or CH.sub.2; m=1-6; the
phenyl is either unsubstituted or substituted with R.sup.6, where
R.sup.6=halogen, CH.sub.3, CF.sub.3, CN, OCH.sub.3 or acetyl;
p=0-6; and 29wherein: W=O, CH.sub.2, CH.sub.2CH.sub.2, or
CH.dbd.CH; R.sup.6 is as defined above; provided that when G is (i)
then R.sup.4.dbd.R.sup.5, and when G is (ii) then
R.sup.4=cyclohexyl, linear or branched C.sub.5-C.sub.7 alkyl, and
R.sup.2, R.sup.3 are different=H and OH; and an ophthalmically
acceptable vehicle therefor.
19. The composition of claim 18, where G is: 30wherein:
Y=CH.sub.2CH.dbd.CH (cis olefin), CH.dbd.CHCH.sub.2 (cis olefin),
or CH.sub.2CH.sub.2CH.sub.2; and Z=trans CH.dbd.CH or
CH.sub.2CH.sub.2; C.ident.C; and an ophthalmically acceptable
vehicle therefor.
20. The composition of claim 18, wherein G is: 31wherein: Z=trans
CH.dbd.CH or CH.sub.2CH.sub.2; C.ident.C; Y.sup.2=halogen or
alkoxy; X.sup.2=O, S, or CH.sub.2; and A=cis CH.dbd.CH,
CH.sub.2CH.sub.2, or C.ident.C; and an ophthalmically acceptable
vehicle therefor.
Description
BACKGROUND OF THE INVENTION
[0001] The present invention relates to novel compounds and
compositions, and methods of their use in the treatment of glaucoma
and ocular hypertension. In particular, the present invention
relates to the use of certain substituted tetrahydrofuran analogs
of D and F series prostaglandins to treat glaucoma and ocular
hypertension.
[0002] Glaucoma is a progressive disease which leads to optic nerve
damage, and, ultimately, total loss of vision. The causes of this
disease have been the subject of extensive studies for many years,
but are still not fully understood. The principal symptom of and/or
risk factor for the disease is elevated intraocular pressure or
ocular hypertension due to excess aqueous humor in the anterior
chamber of the eye.
[0003] The causes of aqueous humor accumulation in the anterior
chamber are not fully understood. It is known that elevated
intraocular pressure ("IOP") can be at least partially controlled
by administering drugs which reduce either the production of
aqueous humor within the eye, such as beta-blockers and carbonic
anhydrase inhibitors, or increase the flow of aqueous humor out of
the eye, such as miotics and sympathomimetics.
[0004] Most types of drugs conventionally used to treat glaucoma
have potentially serious side effects. Miotics such as pilocarpine
can cause blurring of vision and other visual side effects, which
may lead either to decreased patient compliance or to termination
of therapy. Systemically administered carbonic anhydrase inhibitors
can also cause serious side effects, such as nausea, dyspepsia,
fatigue, and metabolic acidosis, which side effects can affect
patient compliance and/or necessitate the termination of treatment.
Moreover, some beta-blockers have increasingly become associated
with serious pulmonary side effects attributable to their effects
on beta-2 receptors in pulmonary tissue. Sympathomimetics may cause
tachycardia, arrhythmia and hypertension. There is therefore a
continuing need for therapies which control the elevated
intraocular pressure associated with glaucoma.
[0005] Prostaglandins, which are metabolite derivatives of
arachidonic acid, have recently been pursued for possible efficacy
in lowering IOP. Arachidonic acid in the body is converted to
prostaglandin G.sub.2, which is subsequently converted to
prostaglandin H.sub.2. Other naturally occurring prostaglandins are
derivatives of prostaglandin H.sub.2. A number of different types
of prostaglandins have been discovered including A, B, D, E, F, G,
I and J-series prostaglandins (EP 0 561 073 A1). Of interest in the
present invention are compounds which are believed to exhibit IOP
lowering mechanisms similar to those exhibited by PGD.sub.2
(formula (I)) and PGF.sub.2.alpha., (formula (II)): 1
[0006] The relationship between prostaglandin DP receptor
activation and IOP lowering effects is not well understood. Various
publications have reported that DP receptor activation leads to
second messenger activation and in particular, to the stimulation
of adenylate cyclase and resultant increases in cAMP levels
(Thierauch, Prostaglandins and their Receptors: II. Receptor
Structure and Signal Transduction, Journal of Hypertension, volume
12, pages 1-5 (1994). Regardless of mechanism, PGD.sub.2 has been
shown to lower IOP (Nakajima, Effects of Prostaglandin D.sub.2 and
its analog, BW245C, on Intraocular Pressure in Humans, Graefe's
Archive Ophthalmology, volume 229, pages 411-413 (1991)). Thus, it
has been of interest in the field to develop synthetic PGD.sub.2
analogs with IOP lowering efficacy.
[0007] Synthetic PGD.sub.2-type analogs have been pursued in the
art (Graefe's Archive Ophthalmology, volume 229, pages 411-413
(1991)). Though some PGD.sub.2-type molecules lower IOP, these
types of molecules have also been associated with undesirable side
effects resulting from topical ophthalmic dosing. Such effects have
included an initial increase in IOP, conjunctival hyperemia,
increases in microvascular permeability, and increases in
eosinophile infiltration (Alm, The Potential of Prostaglandin
Derivatives in Glaucoma Therapy, Current Opinion in Ophthalmology,
volume 4, No. 11, pages 44-50 (1993)).
[0008] Similarly, the relationship of prostaglandin FP receptor
activation and IOP lowering effects is not well understood. It is
believed that FP receptor activation leads to increased outflow of
aqueous humor. Regardless of mechanism, PGF.sub.2.alpha., and some
of its analogs have been shown to lower IOP (Giuffre, The Effects
of Prostaglandin F.sub.2.alpha., the Human Eye, Graefe's Archive
Ophthalmology, volume 222, pages 139-141 (1985); and Kerstetter et
al., Prostaglandin F.sub.2.alpha.-1-Isopropylester Lowers
Intraocular Pressure Without Decreasing Aqueous Humor Flow,
American Journal of Ophthalmology, volume 105, pages 30-34 (1988)).
Thus, it has been of interest in the field to develop synthetic
PGF.sub.2.alpha.a analogs with IOP lowering efficacy.
[0009] Synthetic PGF.sub.2.alpha.-type analogs have been pursued in
the art (Graefe's Archive Ophthalmology, volume 229, pages 411-413
(1991)). Though PGF.sub.2.alpha.-type molecules may lower IOP,
these types of molecules have also been associated with undesirable
side effects resulting from topical ophthalmic dosing. Such effects
include an initial increase in IOP, breakdown of the blood aqueous
barrier and conjunctival hyperemia (Alm, The Potential of
Prostaglandin Derivatives in Glaucoma Therapy, Current Opinion in
Ophthalmology, volume 4, No.11, pages 44-50 (1993)).
[0010] Based on the foregoing, a need exists for the development of
molecules that may activate the prostaglandin DP and/or FP
receptors, yielding a more efficacious lowering of lOP, while
exhibiting fewer or reduced side effects.
[0011] An agent which exhibits comparable or improved efficacy, but
with reduced side effects when compared to other agents, is said to
have an improved therapeutic profile. It is an object of this
invention to provide a class of lOP lowering agents with an
improved therapeutic profile over endogenous prostaglandins, and
methods of their use.
SUMMARY OF THE INVENTION
[0012] The present invention is directed to compositions and
methods of their use in treating glaucoma and ocular hypertension.
In particular, the present invention provides certain classes of
substituted tetrahydrofurans which may possess functional DP and/or
FP receptor agonist activity, and methods of their use in treating
glaucoma and ocular hypertension.
DETAILED DESCRIPTION OF THE INVENTION
[0013] It has unexpectedly been found that substituted
tetrahydrofurans of the present invention exhibit an improved
therapeutic profile in the treatment of glaucoma and ocular
hypertension when compared to natural prostaglandins and many of
their known analogs. The substituted tetrahydrofurans of the
present invention are heptanoic acid derivatives having the
following formula (III): 2
[0014] wherein:
[0015] R=pharmaceutically acceptable ester moiety, CO.sub.2R.sup.1,
CONR.sup.7R.sup.8, CH.sub.2OR.sup.9, or CH.sub.2NR.sup.10R.sup.11,
where R.sup.1.dbd.H or cationic salt moiety; R.sup.7 and R.sup.8
are the same or different=H or alkyl; R.sup.9.dbd.H, acyl, or
alkyl; and R.sup.10 and R.sup.11 are the same or different=H, acyl,
or alkyl; with the proviso that if one of R.sup.10 and
R.sup.11=acyl, then the other=H or alkyl;
[0016] n=0 or 2; 3
[0017] wherein:
[0018] Y=CH.sub.2CH.dbd.CH (cis olefin), CH.dbd.CHCH.sub.2 (cis
olefin), or CH.sub.2CH.sub.2CH.sub.2;
[0019] Z=C.ident.C, trans CH.dbd.CH, or CH.sub.2CH.sub.2;
[0020] Y.sup.2=halogen or alkoxy;
[0021] X.sup.2=O, S, or CH.sub.2; and
[0022] A=cis CH.dbd.CH, CH.sub.2CH.sub.2, or C.ident.C;
[0023] one of R.sup.2 and R.sup.3.dbd.H, and the other=F or OH,
where the OH may be free or functionally modified; or R.sup.2 and
R.sup.3 taken together .dbd.OCH.sub.2CH.sub.2O or double bonded O
(carbonyl); and
[0024] R.sup.4=cyclohexyl, linear or branched C.sub.5-C.sub.7
alkyl, or R.sup.5, wherein:
[0025] R.sup.5=(CH.sub.2).sub.mXphenyl or (CH.sub.2).sub.p Z.sup.2,
where X.dbd.O or CH.sub.2; m=1-6; the phenyl is either
unsubstituted or substituted with R.sup.6, where R.sup.6=halogen,
CH.sub.3, CF.sub.3, CN, OCH.sub.3 or acetyl; p=0-6; and 4
[0026] wherein:
[0027] W.dbd.O, CH.sub.2, CH.sub.2CH.sub.2, or CH.dbd.CH; and
R.sup.6 is as defined above;
[0028] provided that when G is (i) then R.sup.4.dbd.R.sup.5. and
when G is (ii) or (iii) then R.sup.4=cyclohexyl, linear or branched
C.sub.5-C.sub.7 alkyl, and R.sup.2, R.sup.3are different=H and
OH.
[0029] For purposes of the foregoing and following definitions, the
term "pharmaceutically acceptable ester moiety" means any ester
moiety that would be suitable for therapeutic administration to a
patient by any conventional means without significant deleterious
health consequences. Similarly, the term "ophthalmically acceptable
ester moiety" means any pharmaceutically acceptable ester moiety
that would be suitable for ophthalmic application, i.e. non-toxic
and non-irritating. Preferred are ophthalmically acceptable esters
such as alkyl and alkylcycloalkyl esters of carboxylic acids. Most
preferred are C.sub.2-C.sub.5 alkyl esters of carboxylic acids, and
especially isopropyl esters.
[0030] Preferred compounds of the present invention are those of
formula IV: 5
[0031] wherein:
[0032] R.sup.1=H, or C.sub.2-C.sub.5 linear or branched alkyl;
[0033] Y=CH.sub.2CH.dbd.CH (cis olefin), CH.dbd.CHCH.sub.2 (cis
olefin), or CH.sub.2CH.sub.2CH.sub.2;
[0034] Z=C.ident.C, trans CH.dbd.CH, or CH.sub.2CH.sub.2;
[0035] one of R.sup.2 and R.sup.3.dbd.H, and the other=F or OH,
where the OH may be free or functionally modified; or R.sup.2 and
R.sup.3 taken together=OCH.sub.2CH.sub.2O or double bonded O
(carbonyl); and
[0036] R.sup.5=(CH.sub.2).sub.mXphenyl or (CH.sub.2).sub.p Z.sup.2,
where X.dbd.O or CH.sub.2; m=1-6; the phenyl is either
unsubstituted or substituted with R.sup.6, where R.sup.6=halogen,
CH.sub.3, CF.sub.3, CN, OCH.sub.3 or acetyl; p=0-6; and
[0037] Z.sup.2= 6
[0038] wherein:
[0039] W=O, CH.sub.2, CH.sub.2CH.sub.2, or CH.dbd.CH; and R.sup.6
is as defined above.
[0040] Other preferred compounds of this invention include those of
formula V: 7
[0041] wherein:
[0042] R.sup.1=H or C.sub.2-C.sub.5 linear or branched alkyl;
[0043] X.sup.2=O ,or CH.sub.2;
[0044] A =cis CH.dbd.CH, CH.sub.2CH.sub.2, or C.ident.C;
[0045] Y.sup.2=halogen;
[0046] Z=C.ident.C, trans CH.dbd.CH, or CH.sub.2CH.sub.2;
[0047] R.sup.2, R.sup.3 are different=H, and OH; and
[0048] R.sup.4=cyclohexyl, or C.sub.5-C.sub.7 linear or branched
alkyl.
[0049] Especially preferred compounds of this invention are:
1 Compound Number Compound Name Compound Structure VI Isopropyl
[2R(1E,3R),3S(5Z),4R]-7- [Tetrahydro-2-[4-(3-
chlorophenoxy)-3-hydroxy-1- butenyl]-4-hydroxy-3-fur- anyl]-
5-heptenoate. 8 VII Isopropyl [2R(1E,3S),3R(5Z),4S]-7-
[Tetrahydro-4-chloro-2-(3- cyclohexyl-3-hydroxy-1-
propenyl)-3-furanyl]-3-oxa-5- heptenoate. 9 VIII Isopropyl
[2R(1E,3R),3S(4Z),4R]-7- [Tetrahydro-2-[4-(3-
chlorophenoxy)-3-hydroxy-1- butenyl]-4-hydroxy-3-furanyl]-
4-heptenoate. 10 IX Isopropyl [2S(3S),3R(5Z),4S]-7-
[Tetrahydro-4-chloro-2-(3- cyclohexyl-3-hydroxy-1-
propynyl)-3-furanyl]-3-oxa-5- heptenoate. 11
[0050] The PGD.sub.2 type analogs of the present invention (i.e.
Compound III, wherein G is (ii) or (iii)) are believed to be
novel.
[0051] With the exception of: methyl (5Z,13E,
15R)-9.alpha.-acetoxy-15-hyd-
roxy-17-(3-trifluoromethylphenyl)-11-oxa-18,19,20-trinorprosta-5,13
-dienoate and methyl (5Z,13E,
15S)-9.alpha.-acetoxy-15-hydroxy-17-(3-trif-
luoromethylphenyl)-11-oxa-18,19,20-trinorprosta-5,13-dienoate,
syntheses of which have been reported by Verdoorn, et al., S.
African J. Chem., 40:134-138 (1987), the PGF.sub.2.alpha.-type
analogs useful in the present invention (i.e. Compound III, wherein
G is (i)) are also believed to be novel. Related 11-oxa PGFs
outside the scope of the present invention are, however, known and
their syntheses are described in the literature. The 11-oxa analogs
of PGF.sub.2.alpha., and PGF.sub.2.beta.are disclosed in Hanessian,
et al., Carbohydrate Research, 141:221-238 (1985); and Thiem et
al., Liebigs Ann. Chem., 2151-2164 (1985). Arndt, et al., S.
African J. Chem., 34:121-127 (1981), and U.S. Pat. No. 4,133,817,
similarly disclose 11-oxa analogs of PGF.sub.2.alpha.. The entire
contents of these references are hereby incorporated herein.
[0052] In the foregoing illustrations, as well as those provided
hereinafter, wavy line attachments indicate that the configuration
may be either alpha (.alpha.) or beta (.beta.). The dashed lines on
bonds between carbons, e.g. in the bicyclic structural formula for
Z.sup.2, indicate a single or double bond. Two solid lines present
between carbons specify the configuration of the relevant double
bond. Hatched lines indicate the .alpha. configuration, and a solid
triangular line indicates the .beta. configuration.
[0053] In the following Examples 1-8, the following standard
abbreviations are used: g=grams (mg=milligrams); mol=moles
(mmol=millimoles); mL=milliliters; mm Hg=millimeters of mercury;
mp=melting point; bp=boiling point; h=hours; and min=minutes. In
addition, "NMR" refers to nuclear magnetic resonance spectroscopy
and "MS" refers to mass spectrometry.
EXAMPLE 1
Synthesis of (3aR, 4S,
6aR)-Hexahydro-2-Oxofuro-[3,4-b]Furan-4-Carboxaldeh- yde (11)
[0054] The compounds of this invention (both the PGD.sub.2-type and
the PGF.sub.2.alpha.-type 5 analogs) may be prepared from the same
intermediate compound, (3aR, 4S,
6aR)-hexahydro-2-oxofuro[3,4-b]furan-4-c- arboxaldehyde (11) which
is prepared from the readily available
1,2-O-isopropylidene-.alpha.-D-xylofuranose (1) according to
published methodology (Arndt, et al. S. Afr. J. Chem., 34:121-127
(1981); U.S. Pat. No. 4,133,948). The following Scheme 1 outlines
the synthetic route to (11). 12
A:5-O-Benzoyl-1,2-O-Isopropylidene-.alpha.-D-Xylofuranose (2)
[0055] A solution of 1,2-O-isopropylidene-.alpha.-D-xylofuranose 1
(30 g, 0.15 mol) in 360 mL of CH.sub.2Cl.sub.2 was cooled to
0.degree. C. and to it was added 20 mL (0.23 mol) of pyridine and a
catalytic amount (1.0 g) of N,N-dimethylaminopyridine. The
resulting mixture was stirred at 0.degree. C. for 10 min, at which
time 20 mL (0.17 mol) benzoyl chloride was added to it dropwise
over a period of 30 min. The reaction mixture was stirred at
0.degree. C. for an additional 30 min and then quenched by the
addition of 200 mL a saturated solution of NH.sub.4Cl. The reaction
was allowed to warm to room temperature, the layers were separated,
and the aqueous layer was extracted with 3.times.50 mL of
CH.sub.2Cl.sub.2. The combined organic extracts were washed with
3.times.50 mL of a 10% aqueous solution of CuSO.sub.4, 2.times.50
mL of water and brine. The organic solution was dried over
anhydrous MgSO.sub.4, filtered and concentrated. The crude product
mixture was purified by chromatography on silica gel to afford 44.3
g (95% yield) of 2 as a colorless liquid: R.sub..function.0.54 (60%
EtOAc/hexane);
[0056] .sup.1H-NMR (CDCl.sub.3) .delta. 8.03 (m, 2H), 7.40-7.68 (m,
3H), 5.97 (d, 1H, J=3.6 Hz), 4.80 (m, 1H), 4.61 (d, 1H, J=3.4 Hz),
4.37 (m, 2H), 4.20 (s, broad, 1H), 3.35 (broad, 1H), 1.50 (s, 3H),
1.32 (s, 3H).
B:5-O-Benzoyl-1,2-O-Isopropylidene-.alpha.-D-Erythropentofuranos-3-Ulose
(3)
[0057] A solution of oxalyl chloride (2.0 M in CH.sub.2Cl.sub.2,
113 mL, 0.22 mol) in 400 mL of anhydrous CH.sub.2Cl.sub.2 was
cooled to -78.degree. C. under a N.sub.2 atmosphere. To this, a
solution of dimethylsulfoxide (32 mL, 0,45 mol) in 50 mL of
anhydrous CH.sub.2Cl.sub.2 was added dropwise over a period of 5
min. After the resulting solution had been stirred at the same
temperature for 5 min, a solution of 2 (44.3 g, 0.15 mol) in 500 mL
of anhydrous CH.sub.2Cl.sub.2 was added to it dropwise over a
period of 15 min. Stirring was continued at -78.degree. C. for an
additional 15 min. Triethylamine (60 mL, 0.42 mol) was then added
to the reaction mixture, and after a further 15 min at -78.degree.
C. the cold temperature bath was removed, and the stirring was
continued for 10 min. The reaction was then quenched by the
addition of 400 mL of water. The biphasic mixture was allowed to
warm to room temperature and the layers were separated. The aqueous
layer was extracted with 3.times.100 mL of CH.sub.2Cl.sub.2. The
organic extracts were combined and washed with water (3.times.100
mL) and brine and was dried over anhydrous Na.sub.2SO.sub.4.
Filtration and solvent removal afforded crude 3 (42.5 g, 96% yield)
as a pale yellow solid, which was used in the next step without
further purification:
[0058] .sup.1H-NMR (CDCl.sub.3) .delta. 7.97 (m, 2H), 7.40 - 7.65
(m, 3H), 6.14 (d, 1H, J=4.40 Hz), 4.69 (m, 2H), 4.44 (m, 2H), 1.15
(s, 3H), 1.43 (s, 3H).
C: (3aR, 4S, 6RS, 6aR)-4-(Benzoyloxy)Methylhexahydro-6-Hydroxyfuro
[3,4-b]Furan-2-One (6)
[0059] The crude sample of 3 (42.5 g, 0.15 mol),
triethylphosphonoacetate (40.5 g, 0.18 mol) and lithium chloride
(7.6 g, 0.18 mol) were combined and dissolved in 1.0 L of anhydrous
THF. The solution was cooled to 0.degree. C. and to it
triethylamine (25.3 mL, 0.18 mol) was added dropwise. The resulting
slurry was allowed to warm to room temperature gradually, and
stirred under a N.sub.2 atmosphere for 24 h. The reaction mixture
was then poured into 500 mL of a 50% aqueous NaCl solution. The
layers were separated and the aqueous layer was extracted with
2.times.200 mL of EtOAc. The combined organic extracts were dried
over anhydrous MgSO.sub.4. Filtration and solvent removal afforded
50 g of the crude enoate 4 as a mixture of two diastereomers which
was used in the next step: R.sub..function.0.58 and 0.50 (minor and
major isomers, respectively, 50% EtOAc/hexane).
[0060] To a suspension of 30 - 40 g of Raney-Ni (Aldrich, washed to
neutrality with distilled water) in 750 mL of methanol the crude
enoate 4 (50 g) from above was added, and the resulting mixture was
hydrogenated at 65-70 psi, at room temperature in a Parr
high-pressure reactor for 18 h. The reaction mixture was carefully
filtered through a pad of celite. The solids were washed thoroughly
with methanol. The filtrates were combined and evaporated, and the
crude product mixture was purified by passage through a short pad
of silica gel to afford 46.7 g (85% yield for two steps) of 5 as a
colorless liquid. This material was carried onto the next step:
R.sub..function.0.46 (50% EtOAc/hexane);
[0061] .sup.1H NMR (CDCl.sub.3) .delta. 8.03 (m, 2H), 7.40 - 7.65
(m, 3H), 5.88 (d, J=3.6 Hz, 1H), 4.85 (m, 1H), 4.05 - 4.65 (m, 5H),
2.78 (m, 1H), 2.40 (m, 2H), 1.52 (s, 3H), 1.32 (s, 3H), 1.25
(t,J=7.15 Hz, 3H).
[0062] The acetonide 5 (46.7 g, 0.12 mol) obtained above was
dissolved in 250 mL of a 4:1 mixture of glacial acetic acid and
water, and the resulting solution was heated at 100.degree. C. for
3.5 h. The reaction mixture was cooled to room temperature and the
solvent was removed in vacuo. The residue was dissolved in 100 mL
of toluene and the solution was concentrated to afford 39.6 g
(quantitative yield) of 6 as pale yellow viscous liquid:
R.sub..function.0.23 (50% EtOAc/hexane);
[0063] .sup.1H-NMR (CDCl.sub.3) .delta. 8.01 (m, 2H), 7.38 - 7.69
(m, 3H), 5.62 (s, 1H), 4.93 (d, 1H, J=6.02 Hz), 4.30 - 4.70 (m,
3H), 3.20 (m, 1H), 2.50 - 3.05 (m, 2H).
D:(3aR, 4S, 6RS,
6aR)-6-Acetyloxy-4-(Benzoyloxy)Methylhexahydrofuro[3,4-b]-
Furan-2-One (7)
[0064] The lactone 6 (39.6 g, 0.14 mol) was dissolved in 70 mL of
pyridine. To this solution 70 mL of acetic anhydride was added and
the resulting mixture was stirred at room temperature for 20 h. The
solvent was then evaporated and the residue was dissolved in 1.5 L
of EtOAc. This solution was sequentially washed with 2.times.150 mL
of water, 3.times.150 mL of a 0.25 N HCl solution water,
1.times.150 mL water and 1.times.100 mL brine. The organic layer
was dried over anhydrous MgSO.sub.4, filtered and concentrated. The
crude product was isolated as a yellow solid which was titurated
with hot ether to afford 29.0 g of a white crystalline solid which
was found to be a single diastereomer of the acetate by
.sup.1H-NMR. The mother liquor was concentrated and purified by
chromatography on silica gel to afford 6.7 g of a mixture of
diastereomeric acetates as a yellow liquid. The combined yield of 7
being 87%: R.sub..function.0.3 (60% EtOAc/hexane);
[0065] .sup.1H-NMR (CDCl.sub.3) .delta. (for major isomer only)
8.03 (m, 2H), 7.42 - 7.68 (m, 3H), 6.41 (s, 1H), 5.01 (d, 1H, J=6.3
Hz), 4.45 (s, broad, 3H), 3.22 (m, 1H), 2.90 (dd, 1H, J=14.4, 9.0
Hz), 2.62 (dd, 1H, J=14.4, 3.4 Hz), 2.03 (s, 3H).
E:(3aR, 4S, 6RS,
6aR)-4-(Benzoyloxy)Methylhexahydro-6-Phenylthiofuro[3,4-b-
]Furan-2-One (8)
[0066] To a suspension of 7 (35.7 g, 0.11 mol) and thiophenol (14.8
mL, 0.13 mol) in 220 mL of a 4:1 mixture of anhydrous toluene and
dichloromethane at room temperature, boron trifluoride etherate
(6.9 mL, 0.05 mol) was added dropwise. The resulting mixture was
stirred at the same temperature for 6.5 h and then carefully poured
into a biphasic mixture of 1000 mL of EtOAc and 100 mL of a
saturated aqueous solution of NaHCO.sub.3 (sat. NaHCO.sub.3). The
layers were separated and the organic layer was washed with
2.times.100 mL of saturated NaHCO.sub.3, 100 mL of water and 100 mL
of brine. The organic layer was dried over anhydrous MgSO.sub.4,
filtered and concentrated to afford a yellow liquid. This material
was dissolved in 50 mL of CHCl.sub.3, and to it was added 200 mL of
ether and 50 mL of hexane. The resulting solution was briefly
cooled to -78.degree. C. to induce crystallization. White powdery
solid formed which was filtered off and washed with cold ether to
afford 29.6 g of 8 (72% yield) as a mixture of two diastereomers:
R.sub..function.0.70 and 0.53 (minor and major isomers,
respectively, 60% EtOAc/hexane);
[0067] .sup.1H-NMR (CDCl.sub.3) .delta. (for major isomer only)
8.01 (m, 2H), 7.42 - 7.70 (m, 5H), 7.27 (m, 3H), 5.89 (d, 1H, J=5.2
Hz), 5.29 (dd, 1H, J=7.7, 5.2 Hz), 4.55 (m, 2H), 4.48 (m, 1H), 2.60
- 3.12 (m, 3H).
F:(3aR, 4S, 6aR)-4-(Bezoyloxy)Methylhexahydrofuro[3,4-b]Furan-2-One
(9)
[0068] A 3-neck, 1000 mL round-bottom flask, equipped for overhead
mechanical stirring, was charged with 29.6 g of 8 (80 mmol), 500 mL
of ethanol and approximately 30 g of Raney-Ni (Aldrich, which had
been washed to neutrality with distilled water). The resulting
slurry was heated at reflux for 5 h while stirring vigorously. The
reaction mixture was then cooled to room temperature, and the
solids were carefully filtered off through a pad of celite. The
residue was washed thoroughly with ethanol, and the combined
filtrates were concentrated to afford a yellow solid which was
purified by chromatography on silica gel to afford 7.63 g (36%
yield) of 9 as a white solid. A small sample was recrystallized
from acetone/hexane to afford colorless needles:
[0069] mp 89.5-90.0.degree. C., [.alpha.].sub.D.sup.22+3.18 (c=0.8
in CHCl.sub.3); R.sub..function.0.36 (60% EtOAc/hexane);
.sup.1H-NMR (CDCl.sub.3) .delta. 8.01 (m, 2H), 7.40 - 7.65 (m, 3H),
5.15 (m, 1H), 4.41 (m, 2H), 4.05 - 4.32 (m, 3H), 2.80 - 3.05 (m,
2H), 2.56 (d, 1H, J=15.7 Hz); MS m/z at 263 for (M+H).sup.+.
G:(3aR, 4S, 6aR)-Hexahydro-2-Oxofuro[3,4-b]Furan-4-Carboxaldehyde
(11)
[0070] To a solution of the benzoate 9 (2.63 g, 10.0 mmol) in 50 mL
of warm methanol was added 1.4 g (10.0 mmol) of solid
K.sub.2CO.sub.3. The resulting slurry was stirred at room
temperature for 2.5 h, at which time 150 mL of water was added and
the mixture was treated with Amberlyst-15 (purified and activated)
until the solution was at pH 2-3. The resin was filtered and washed
with 50 mL of water, and the filtrates were combined and
concentrated to approximately 200 mL. This solution was extracted
with 3.times.50 mL of EtOAc, the organic extracts were discarded
and the aqueous phase was evaporated in vacuo. The residue was
taken up in 50 mL of toluene and the solvent was evaporated; this
drying procedure was repeated twice. The product hydroxylactone 10
thus obtained (1.64 g, 95% yield) was isolated as a pale yellow
liquid. This material was used without further purification:
[0071] .sup.1H-NMR (d.sub.6-DMSO) .delta. (crude sample) 5.12 (m,
1H), 4.81 (t, 1H, J=5.6 Hz, OH), 3.98 (dd, 1H, J=10.3, 4.1 Hz),
3.85 (d, 1H, J=10.5 Hz), 3.75 (m, 1H), 3.44 (m, 2H), 2.85 (m, 2H),
2.48 (m, 1H).
[0072] A solution of oxalyl chloride (2.0 M in CH.sub.2Cl.sub.2,
5.4 mL, 10.8 mmol) in 25 mL anhydrous CH.sub.2Cl.sub.2 was cooled
to -78.degree. C. under a N.sub.2 atmosphere. To this, a solution
of DMSO (1.5 mL, 21.6 mmol) in 5.0 mL of CH.sub.2Cl.sub.2 was added
dropwise. The resulting mixture was stirred for 5 min, and then a
solution of the hydroxylactone 10 obtained above (1.14 g, 7.21
mmol) in 50 mL of anhydrous CH.sub.2Cl.sub.2 was added dropwise.
After 15 min at -78.degree. C., triethylamine (2.85 mL, 20.2 mmol)
was added to the reaction and stirring was continued for an
additional 15 min at -78.degree. C. The reaction was then allowed
to warm to room temperature and filtered through a pad of celite.
The filter cake was washed with CH.sub.2Cl.sub.2, the filtrates
were combined and concentrated to approximately 10 mL; this
solution was applied to a column of silica gel for chromatographic
purification. The aldehyde 11 (0.9 g, 80% yield) was isolated as a
colorless liquid: R.sub..function.0.6 (acetone);
[0073] .sup.1H-NMR (CDCl.sub.3) .delta. 9.71 (s, 1H), 5.10 (m, 1H),
4.24 (m, 1H), 3.65 - 3.89 (m, 2H), 2.96 (m, 1H), 2.64 (m, 1H), 1.85
(m, 1H).
EXAMPLE 2
Synthesis of Isopropyl
[2R(1E,3R),3S(5Z),4R]-7-[Tetrahydro-2-[4-(3-Chlorop-
henoxy)-3-Hydroxy-1-Butenyl]-4-Hydroxy-3-Furanyl]-5-Heptenoate
(VI)
[0074] Compound VI may be prepared according to the method
described by the following Scheme 2. 13
A: [3aR, 4R(1E),
6aR]-4-[4-(3-Chlorophenoxy)-3-Oxo-1-Butenyl]Hexahydrofuro-
[3,4-b]-Furan-2-One (12)
[0075] A solution of
dimethyl-3-(3-chlorophenoxy)-2-oxopropylphosphonate (2.34 g, 8
mmol) and LiCl (0.29 g, 6.9 mmol) in 15 mL of anhydrous THF was
cooled to 0.degree. C. under N.sub.2 atmosphere and to it
triethylamine (0.97 mL, 6.9 mmol) was added dropwise. A white
slurry formed, which was stirred for 3 min at 0.degree. C., at
which time a solution of the aldehyde 11 (0.9 g, 5.76 mmol) in 15
mL of anhydrous THF was added to it. The resulting mixture was
stirred at 0.degree. C. for 1 h, and then partitioned between 100
mL of water and 250 mL of EtOAc. The layers were separated and the
organic phase was washed with water and brine, and dried
(MgSO.sub.4). Filtration and solvent removal afforded a yellow
liquid which was purified by chromatography on silica gel to yield
1.13 g of the enone 12 (60% yield) as a colorless, viscous liquid:
R.sub..function.0.29 (60% EtOAc/hexane);
[0076] .sup.1H-NMR (CDCl.sub.3) .delta. 7.22 (m, 1H), 6.85 - 7.08
(m, 3H), 6.79 (m, 1H), 6.65 (dd, 1H, J=16.2, 1.6 Hz), 5.10 (m, 1H),
4.69 (s, 2H), 4.38 (m, 1H), 4.10 (m, 2H), 2.88 (m, 2H), 2.57 (m,
1H).
B:[3aR, 4R(1E,3RS),
6aR]-4-[4-(3-Chlorophenoxy)-3-Hydroxy-1-Butenyl]Hexahy-
drofuro[3,4-b]Furan-2-One (13)
[0077] A mixture of 12 (1.0 g, 3.10 mmol) and CeCl.sub.3.7H.sub.2O
(2.3 g, 6.2 mmol) was taken up in a mixture of CH.sub.3OH (25 mL)
and CHCl.sub.3 (10 mL), and the solution was cooled to 0.degree. C.
To this cold solution NaBH.sub.4 (0.23 g, 6.2 mmol) was added in
small portions over a period of 5 min. (CAUTION: vigorous hydrogen
gas evolution occurs). The resulting mixture was stirred for an
additional 3 min at 0.degree. C., and then poured into 100 mL of
0.5 N HCl solution. The aqueous solution was extracted with
3.times.50 mL of CHCl.sub.3. The organic extracts were combined and
washed with 3.times.50 mL of water and brine, and dried over
anhydrous MgSO.sub.4. Filtration and solvent removal afforded an
oil which was purified by silica gel chromatography to give 0.71 g
(70% yield) of 13 (a diastereomeric mixture of alcohols) as a
colorless liquid: R.sub..function.0.14 (60% EtOAc/hexanes);
[0078] .sup.1H-NMR (CDCl.sub.3) .delta. 7.21 (m, 1H), 6.95 (m, 2H),
6.78 (m, 1H), 5.89 (s, broad, 2H), 5.11 (m, 1H), 4.56 (m, 1H), 4.20
(m, 2H), 4.01 (m, 2H), 3.89 (m, 1H), 2.85 (m, 2H), 2.57 (m, 2H);
.sup.13C-NMR (CDCl.sub.3) .delta. 175.62 (C.dbd.O), 158.96 (O--Ar),
134.93 (Cl--Ar), 130.95 and 130.80 (CH), 130.33 (CH), 129.86 and
129.75 (CH), 121.55 (CH), 115.02 (CH), 113.00 (CH), 84.57 and 84.51
(CH), 84.07 (CH), 72.48 (CH.sub.2), 71.68 (CH.sub.2), 69.82 and
69.76 (CH), 44.80 (CH), 32.49 (CH.sub.2).
C:[3aR, 4R(1E,3RS),
6aR]-4-[4-(3-Chlorophenoxy)-3-(Tetrahydropyran-2-yl)Ox-
y-1-Butenyl]-Hexahydrofuro[3,4-b]Furan-2-One (14)
[0079] A solution of 13 (0.71 g, 2.19 mmol) in 20 mL of
CH.sub.2Cl.sub.2 was cooled to 0.degree. C. To this 0.5 mL (4.38
mmol) of 3,4-dihydro-2H-pyran was added followed by a catalytic
amount of p-toluenesulfonic acid (10 mg). The reaction was stirred
at 0.degree. C. for 15 min and then quenched by the addition of 10
mL of a saturated aqueous solution of NaHCO.sub.3. The layers were
separated and the aqueous layer was extracted with 2.times.10 mL of
dichloromethane. The combined organic extracts were dried
(MgSO.sub.4), filtered and concentrated. The product 14 (0.78 g,
91% yield) was isolated as a colorless liquid after chromatography
of the crude on silica gel: R.sub..function.0.28 (60%
EtOAc/hexane).
D:Methyl [2R(1E,3RS), 3S(5Z),
4R]-7-[Tetrahydro-2-[4-(3-Chlorophenoxy)-3-(-
Tetrahydropyran-2-yl)Oxy-1-Butenyl]-4-Hydroxy-3-Furanyl]-5-Heptenoate
(16)
[0080] A solution of the lactone 14 (0.78 g, 1.9 mmol) in 20 mL of
anhydrous THF was cooled to -78.degree. C. under a N.sub.2
atmosphere, and diisobutylaluminum hydride (DIBAL-H, 1.9 mL, 1.5 M
in toluene, 2.8 mmol) was added to it dropwise. The resulting
mixture was stirred at -78.degree. C. for 1.5 h and then quenched
at the same temperature by the careful addition of 5 mL of
methanol. The mixture was allowed to warm to room temperature,
diluted with 50 mL of EtOAc and treated with 100 mL of a saturated,
aqueous potassium sodium tartrate solution, with vigorous stirring,
for 1 h. The layers were separated and the aqueous layer was
extracted with 3.times.10 mL of EtOAc. The combined organic
extracts were dried (MgSO.sub.4), filtered and concentrated. The
crude product thus obtained was purified by passage through a short
pad of silica gel to afford the intermediate lactol 15 (0.68 g, 87%
yield) as a colorless liquid: R.sub..function.0.15 (60%
EtOAc/hexane).
[0081] To a suspension of (4-carboxybutyl)triphenylphosphonium
bromide (2.2 g, 4.9 mmol) in 20 mL anhydrous THF at 0.degree. C.,
potassium tert-butoxide (t-BuOK, 10.0 mL, 1.0 M THF, 10.0 mmol) was
added dropwise and the mixture was stirred at 0.degree. C. for 30
min. A solution of the lactol 15 obtained above (0.68 g, 1.65 mmol)
in 50 mL of THF was then added to it dropwise. The resulting
mixture was allowed to warm to room temperature and was stirred at
that temperature for 16 h. The reaction was quenched by pouring it
into a saturated aqueous solution of ammonium chloride (50 mL)
which had been acidified to pH 2-3 with dilute aqueous HCl
solution. The mixture was extracted with EtOAc (5.times.25 mL), and
the combined organic extracts were washed with water (1.times.25
mL) and brine (1.times.25 mL) and dried over anhydrous
Na.sub.2SO.sub.4. The solution was filtered, concentrated to
approximately 10 mL and then cooled to 0.degree. C. This solution
was treated with an excess of ethereal diazomethane at 0.degree. C.
The excess diazomethane was evaporated off by bubbling N.sub.2
through the solution for 1 h. The resulting pale yellow solution
was concentrated and applied to a column of silica gel for
purification by chromatography. The methyl ester 16 (0.38 g, 50%
yield, mixture of diastereomers) was isolated as a colorless
liquid: R.sub..function.0.27 (60% EtOAc/hexane).
E:Methyl [2R(1E,3RS), 3S(5Z),
4R]-7-[Tetrahydro-2-[4-(3-Chlorophenoxy)-3-H-
ydroxy-1-Butenyl]-4-Hydroxy-3-Furanyl]-5-Heptenoate (17)
[0082] The compound 16 (0.37 g, 0.74 mmol) was dissolved in a
mixture of 10 mL of methanol and 0.5 mL of water. The solution was
cooled to 0.degree. C. and to it was added about 10 drops of 12 N
HCl. The resulting mixture was stirred at 0.degree. C. for 15 min
and then at room temperature for 45 min, at which time the reaction
was quenched with solid NaHCO.sub.3 (0.2 g). The mixture was
transferred to a separatory funnel containing 25 mL each of
CHCl.sub.3 and saturated aqueous solution of NaHCO.sub.3. The
layers were separated and the aqueous layer was extracted with
4.times.25 mL of CHCl.sub.3. The combined organic extracts were
dried (Na.sub.2SO.sub.4), filtered and concentrated. The crude was
purified by chromatography on silica gel to afford the diol 17
(0.28 g, 88% yield, mixture of diastereomers) as a colorless
liquid: R.sub..function.0.18 (80% EtOAc/hexane); .sup.1H-NMR
(CDCl.sub.3) .delta. 7.20 (m, 2H), 6.80 - 6.92 (m, 3H), 5.87 (m,
2H), 5.45 (m, 2H), 4.58 (m, 1H), 4.35 (m, 1H), 3.80 - 4.20 (m, 6H),
3.66 (s, 3H), 2.22 - 2.60 (m, 4H), 2.15 (m, 4H), 1.69 (m, 2H); MS
m/z at 447 for (M+Na).sup.+.
F:Isopropyl [2R(1E,3R), 3S(5Z),
4R]-7-[Tetrahydro-2-[4-(3-Chlorophenoxy)-3-
-Hydroxy-1-Butenyl]-4-Hydroxy-3-Furanyl]-5-Heptenoate (VI)
[0083] The diastereomeric mixture of methyl esters 17 (0.28 g, 0.65
mmol) was dissolved in 20 mL of methanol containing 2 mL of water.
To this solution 0.2 g (4.76 mmol) of LiOH was added and the
resulting mixture was stirred at room temperature for 5.5 h. The
reaction mixture was then transferred to a separatory funnel
containing 50 mL of CHCl.sub.3 and 25 mL of a 1N aqueous HCl
solution; the layers were separated and the aqueous phase was
extracted with 4.times.25 mL portions of CHCl.sub.3. The organic
extracts were combined and washed with 3.times.10 mL of water and
1.times.25 mL of brine and dried over anhydrous Na.sub.2SO.sub.4.
The solution was filtered, concentrated and purified by HPLC
(RP-18, acetonitrile/water/TFA) to afford 18 (0.25 g, 93% yield,
diastereomeric mixture) as a clear colorless liquid:
[0084] .sup.1H-NMR (CDCl.sub.3) .delta. 7.22 (m, 2H), 6.85 - 7.05
(m, 3H), 5.86 (m, 2H), 5.44 (m, 2H), 4.84 (broad, 2H), 4.61 (m,
1H), 4.37 (m, 1H), 3.86 - 4.20 (m, broad, 6H), 2.00 - 2.65 (m, 6H),
1.50 - 1.95 (m, 3H); .sup.13C-NMR (CDCl.sub.3) .delta. 177.58
(C.dbd.O), 159.08 (O-Ar), 134.89 (Cl-Ar), 133.22 (CH), 132.46 (CH),
130.28, 129.84 (CH), 128.01 (CH), 121.43 (CH), 115.13, 115.10 (CH),
113.02 (CH), 82.26, 82.03 (CH), 75.54, 75.48 (CH.sub.2), 72.58,
72.50 (CH), 71.59, 71.55 (CH.sub.2), 70.48, 70.03 (CH), 51.39,
51.34 (CH), 32.68 (CH.sub.2), 26.19 (CH.sub.2), 24.41, 24.30
(CH.sub.2), 22.33, 22.18 (CH.sub.2); MS m/z at 433 for
(M+Na).sup.+.
[0085] A solution of the acid 18 (0.25 g, 0.61 mmol) in 15 mL of
acetone was treated with 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU;
0.66 mL, 4.4 mmol) for 30 min at room temperature. Isopropyl iodide
(0.36 mL, 3.7 mmol) was then added to the reaction mixture, and the
resulting solution was stirred at room temperature for 18 h. The
solvent was then evaporated and the residue was partitioned between
50 mL of Et.sub.2O and 10 mL of water. The layers were separated
and the organic layer was washed with 3.times.10 mL of a 10%
aqueous CuSO.sub.4 solution and 1.times.10 mL of brine. The organic
phase was dried (Na.sub.2SO.sub.4), filtered and concentrated. The
crude was applied to a column of silica gel and the two
diastereomeric esters were isolated separately, yielding compound
VI (81 mg, 32% yield) as a colorless oil: R.sub..function.0.54
(EtOAc);
[0086] .sup.1H-NMR (CDCl.sub.3) .delta. 7.19 (m, 1H), 6.92 (m, 2H),
6.80 (m, 1H), 5.86 (m, 2H), 5.42 (m, 2H), 5.05 (septet, J=6.2 Hz,
1H), 4.58 (m, 1H), 4,35 (m, 1H), 4.20 - 3.82 (broad m, 5H), 2.68
(d, J=4.5 Hz, 1H), 2.45 - 2.00 (m, 7H), 1.89 - 1.60 (m, 4H), 1.24
(d, J=6.5 Hz, 6H); .sup.13C-NMR (CDCl.sub.3) .delta. 173.42,
159.20, 134.89, 132.48, 130.57, 130.35, 130.25, 128.06, 121.35,
115.11, 113.05, 82.02, 75.43, 72.70, 71.87, 70.14, 67.71, 51.09,
33.99, 26.63, 24.77, 22.57, 21.81; MS m/z at 475 for (M+Na).
EXAMPLE 3
Synthesis of Isopropyl
[2R(1E,3S),3R(5Z),4S]-7-[Tetrahydro-4-Chloro-2-(3-C-
yclohexyl-3-Hydroxy-1-Propenyl)-3-Furanyl]-3-Oxa-5-Heptenoate
(VII)
[0087] Compound VII may be prepared as described by the following
Scheme 3. 14
A:[3aR, 4R(1E),
6aR]-4-(3-Cyclohexyl-3-Oxopropenyl)Hexahydrofuro[3,4-b]Fur-
an-2-One (19)
[0088] A 500 mL 1-neck flask was charged with
dimethyl-(2-cyclohexyl-2-oxo- )ethylphosphonate (6.9 g, 29.6 mmol),
LiCl (1.07 g, 25.4 mmol) and 40 mL of anhydrous THF. The mixture
was cooled to 0.degree. C. and triethylamine (3.6 mL, 25.4 mmol)
was added to it in a dropwise manner. The white slurry formed was
stirred for 10 min and then a solution of
(3aR,4S,6aR)-hexahydro-2-oxofuro[3,4-b]furan-4-carboxaldehyde (11;
3.31 g, 21.2 mmol) in a mixture of 60 mL of anhydrous THF and 10 mL
of anhydrous CH.sub.2Cl.sub.2 was added to it dropwise. The
resulting mixture was allowed to warm to room temperature and was
stirred at that temperature for 18 h. The reaction mixture was
worked up (250 mL of EtOAc and 50 mL of water) and purified by
silica gel chromatography. The white solid obtained was
recrystallized from hexane using a minimum amount of EtOAc to
effect solubilization. The enone 19 (2.2 g, 43% yield) was isolated
as white needles:
[0089] mp. 80.0-82.5.degree. C.; R.sub..function.0.37 (60%
EtOAc/hexane); [.alpha.].sub.D.sup.22+47.9.degree.(c=0.6,
CH.sub.3OH); .sup.1H-NMR (CDCl.sub.3) .delta. 6.72 (dd, J=16.6, 4.5
Hz, 1H), 6.45 (dd, J=16.6, 1.5 Hz, 1H), 5.12 (m, 1H), 4.38 (m, 1H),
4.20 - 4.05 (m, 2H), 2.85 (m, 2H), 2.52 (m, 2H), 1.95 - 1.58 (m,
5H), 1.50 - 1.10 (m, 5H); .sup.13C-NMR(CDCl.sub.3) .delta. 202.32,
175.18, 141.00, 127.81, 83.86, 83.80, 72.74, 49.64, 44.65, 32.86,
28.31, 25.76, 25.57; MS m/z at 265 for (M+H).sup.+.
B:[3aR, 4R(1E,3RS),
6aR]4-(3-Cyclohexyl-3-Hydroxypropenyl)Hexahydrofuro[3,-
4-b]Furan-2-One (20)
[0090] To a solution of CeCl.sub.3.7H.sub.2O (2.23 g, 6.0 mmol) in
50 mL of methanol, the enone 19 (0.8 g, 3.0 mmol) was added and the
resulting solution was cooled to 0.degree. C. The cold solution was
treated with solid NaBH.sub.4 in small portions (0.23 g, 6.0 mmol)
over a period of 5 min. (CAUTION: vigorous H.sub.2 gas evolution
occurs). After an additional 3 min at 0.degree. C., the reaction
was quenched by pouring it into 50 mL of a 0.5 N aqueous HCl
solution. The aqueous layer was extracted with 4.times.75 mL of
CHCl.sub.3 and the organic extracts were washed with water and
brine and dried (MgSO.sub.4). Filtration and solvent removal
afforded the crude, which was purified by silica column
chromatography to afford 20 (0.69 g, 85% yield) as an equimolar
mixture of two diastereomers: R.sub..function.0.2 (60%
EtOAc/hexane); .sup.1H-NMR (CDCl.sub.3) .delta. 5.77 (m, 2H), 5.12
(m, 1H), 4.25 - 3.82 (m, 4H), 2.78 (m, 2H), 2.45 (m, 1H), 1.90 -
0.85 (broad m, 12H).
C:[3aR, 4R(1E,3RS),
6aR)-4-[3-Cyclohexyl-3-(Tetrahydropyran-2-yl)Oxypropen-
yl]Hexahydrofuro[3,4-b]Furan-2-One (21)
[0091] A solution of the alcohol 20 (0.69 g, 2.6 mmol) and
3,4-dihydro-2H-pyran (0.6 mL, 5.2 mmol) in 25 mL of
CH.sub.2Cl.sub.2 was cooled to 0.degree. C. After 3 min, a
catalytic amount of p-toluenesulfonic acid (20 mg) was added. The
reaction mixture was stirred at 0.degree. C. for 20 min and then
quenched by the addition of 10 mL of a saturated aqueous solution
of NaHCO.sub.3. The layers were separated and the organic phase was
washed with brine and dried (K.sub.2CO.sub.3). The compound 21 (0.8
g, 88% yield) was isolated as a colorless liquid after
chromatography of the crude on silica: R.sub..function.0.5 (60%
EtOAc/hexane).
D:[2R(1E,3S),3R,
4R]-2-[3-Cyclohexyl-3-(Tetrahydropyran-2-yl)Oxy-1-Propeny-
l]-3-(2-Triethylsilyloxyethyl)-4-Triethylsilyloxytetrahydrofuran
(23)
[0092] A suspension of lithium aluminum hydride (2.0 g, 54 mmol) in
dry THF (100 mL) was cooled to 0.degree. C., and to it a solution
of the lactone 21 (9.42 g, 27 mmol) in THF (100 mL) was added
dropwise. The mixture was gradually allowed to warm to room
temperature, and was stirred at that temperature for 14 h. The
reaction was then cooled to 0.degree. C. in an ice bath, and
quenched by adding 10 mL of methanol dropwise. The ice bath was
removed and the suspension was sequentially treated with 2 mL of
water, 2 mL of a 15% aqueous NaOH solution and 6 mL of water. The
resulting suspension was filtered through a pad of MgSO.sub.4, and
the filter cake was washed with 100 mL of EtOAc. The filtrate was
concentrated and the residue was subjected to silica gel
chromatography to afford 7.14 g (75% yield) of the diol 22 (mixture
of diastereomers) as a colorless liquid: R.sub..function.0.25
(EtOAc);
[0093] .sup.1H-NMR (d.sub.6-DMSO) .delta. (partial spectrum)
5.65-5.30 (m, broad, 2H, olefinic), 4.75 (m, 1H, OH), 4.45 (m, 1H,
OH).
[0094] A solution of the diol 22 (1.84 g, 5.2 mmol) in
CH.sub.2Cl.sub.2 (60 mL) was cooled to 0.degree. C., and to it was
added triethylamine (4.4 mL, 31.2 mmol) and a catalytic amount of
N,N-dimethylamino pyridine (DMAP, 50 mg). The resulting mixture was
stirred for 3 min, and then triethylsilyl chloride (2.6 mL, 15.6
mmol) was added to it. The reaction mixture was stirred for 1 h at
0.degree. C., and then at room temperature for an additional hour.
The reaction was then poured into 100 mL of water, and the biphasic
mixture was extracted with ether (5.times.50 mL). The organic
extracts were combined and washed with brine and dried over
anhydrous K.sub.2CO.sub.3. Filtration and solvent removal gave an
oil, which was subjected to column chromatography on silica gel;
the two C15 diastereomers were separated and the desired isomer 23
(1.63 g, 54%) was obtained as a colorless oil: R.sub..function.0.21
(20% Et.sub.2O/hexane);
[0095] .sup.1H-NMR (CDCl.sub.3) .delta. 5.50 (m, 2H), 4.70 (broad
m, 1H), 4.32 (broad m, 1H), 4.15-3.40 (broad, 8H), 2.15-1.45
(broad, 15H),1.35-0.80 (m, 20H), 0.60 (m, 12H).
E:
[2R(1E,3S),3R,4R]-2-[Tetrahydro-2-[3-Cyclohexyl-3-(Tetrahydropyran-2-yl-
)Oxy-1-Propenyl]-4-Triethylsilyloxy-3-Furanyl]Acetaldehyde (24)
[0096] A solution of oxalyl chloride (2.8 mL, 2.0
M/CH.sub.2Cl.sub.2, 5.60 mmol) in 15 mL of CH.sub.2Cl.sub.2 was
cooled to -78.degree. C., and to it a solution of DMSO (0.80 mL,
11.20 mmol) in 1.0 mL of CH.sub.2Cl.sub.2 was added dropwise. The
mixture was stirred for 3 min, at which time a solution of the
substrate 23 (1.63 g, 2.80 mmol) in 15 mL of CH.sub.2Cl.sub.2 was
added to it. The resulting mixture was stirred at -78.degree. C.
for 3 h, and then treated with triethylamine (2.0 mL, 14.0 mmol).
The cold temperature bath was removed and the reaction was allowed
to warm to room temperature and then worked up by partitioning
between water and CH.sub.2Cl.sub.2. The crude was subjected to
silica gel chromatography to afford 24 (1.02 g, 78% yield) as a
colorless liquid: R.sub..function.0.15 (10% EtOAc/hexane);
[0097] .sup.1H-NMR (CDCl.sub.3) .delta. (partial spectrum) 9.84 (s,
1H, aldehyde), 5.53 (m, 2H, olefinic), 4.69 (m, 1H), 4.50 (m, 1H),
4.15 (m, 2H), 2.80 (m, 1H).
F:Methyl
[2R(1E,3S),3R(2EZ),4R]-4-[Tetrahydro-2-[3-Cyclohexyl-3-(Tetrahydr-
opyran-2-yl)Oxy-1-Propenyl]-4-Triethylsilyloxy-3-Furanyl]-2-Butenoate
(25)
[0098] A solution containing
bis(2,2,2-trifluoroethyl)(methoxycarbonylmeth- yl)phosphonate (0.86
g, 2.6 mmol) and 18-crown-6 (1.74 g, 6.6 mmol) in THF (30 mL) was
cooled to -78.degree. C., and to it a solution of potassium
bis(trimethylsilyl)amide (KHMDS, 5.2 mL, 0.5 M in toluene, 2.6
mmol) was added dropwise. The resulting solution was stirred at
-78.degree. C. for 20 min, at which time a solution of the aldehyde
24 (1.02 g, 2.2 mmol) in 10 mL of THF was introduced via cannula.
The reaction was stirred at the same temperature for 2 h, after
which it was rapidly warmed to 0.degree. C. (ice bath) and quenched
at that temperature by adding 50 mL of a saturated aqueous solution
of NH.sub.4Cl. The resulting mixture was allowed to warm to room
temperature and was partitioned between water and EtOAc. The
organic layers were combined, washed with water, brine and dried
(MgSO4). The product 25 (0.94 g, 81% yield), as a mixture of
diastereomers, was isolated as a colorless liquid after
chromatography on silica: R.sub..function.0.50 (30%
EtOAc/hexane);
[0099] .sup.1H-NMR (CDCl.sub.3) .delta. (major isomer only) 6.28
(m, 1H), 5.80 (m, 1H), 5.55 (m, 2H), 4.68 (m, 1H), 4.38 (m, 1H),
4.18 (m, 1H), 4.02 (m, 1H), 3.70 (s, 3H), 2.80 (m, 2H), 0.95 (m,
9H), 0.61 (m, 6H).
G:
[2R(1E,3S)3S(2Z),4R]-4-[Tetrahydro-2-[3-Cyclohexyl-3-(Tetrahydropyran-2-
-yl)Oxy-1-Propenyl]-4-Hydroxy-3-Furanyl]-2-Butenol (27)
[0100] A solution of the enoate 25 (0.94 g, 1.8 mmol) in 20 mL of
THF was cooled to 0.degree. C., and DIBAL-H (3.6 mL, 1.5 M in
toluene, 5.4 mmol) was added to it dropwise over 5 min. The
reaction mixture was stirred at 0.degree. C. for 2 h, and then
quenched at the same temperature by carefully adding 5 mL of
methanol. The reaction was worked up by stirring it with a
saturated aqueous solution of potassium sodium tartrate for 1 h at
room temperature. The layers were separated and the aqueous layer
was extracted with 3.times.25 mL of ether. The organic extracts
were combined and dried, filtered and evaporated to afford an oil
which was purified by passage through a short plug of silica. The
mixture of allylic alcohol isomers 26 (0.77 g, 82% yield) was
obtained as a colorless liquid: R.sub..function.0.23 (30%
EtOAc/hexane).
[0101] A solution of the allylic alcohol mixture obtained above
(0.77 g, 1.56 mmol) in 50 mL of THF was treated with
tetra-n-butylammonium fluoride (8.0 mL, 1.0 M in THF, 8.0 mmol) at
room temperature for 10 min. The mixture was then poured into water
and extracted with ether (3.times.25 mL). The combined ether layers
were washed with water and brine and dried (MgSO.sub.4); the crude
oil was subjected to chromatography to afford the desired major
isomer 27 (0.54 g, 91% yield) as a white semi-solid:
R.sub..function.0.31 (EtOAc);
[0102] .sup.1H-NMR (CDCl.sub.3) .delta. (partial spectrum)5.90-5.45
(broad m, 4H), 4.68 (m, 1H), 4.35 (m, 2H), 4.20-3.65 (broad m, 6H),
3.45 (m, 1H), 2.60 (m, 2H); MS m/z at 403 for (M+Na).sup.+.
H:Isopropyl
[2R(1E,3S),3S(5Z),4R]-7-[Tetrahydro-2-[3-Cyclohexyl-3-(Tetrahy-
dropyran-2-yl)Oxy-1-Propenyl]-4-Hydroxy-3-Furanyl]-3-Oxa-5-Heptenoate(28)
[0103] A solution of the diol 27 (0.54 g, 1.42 mmol) in 15 mL of
toluene was cooled to 0.degree. C., and to it were added
nBu.sub.4NHSO.sub.4 (0.1 g) and aqueous NaOH (15 mL, 25% w/v). The
resulting mixture was stirred vigorously for 5 min, at which time
isopropyl bromoacetate (0.77 g, 4.26 mmol) was added to it
dropwise. After stirring at 0.degree. C. for an additional 30 min,
the reaction mixture was poured into ether/water mixture (50 mL
each). The layers were separated and the aqueous layer was
extracted with ether (3.times.25 mL). The organic extracts were
combined and washed with a saturated aqueous solution of
KH.sub.2PO.sub.4 (10 mL), water (10 mL) and brine (10 mL) and dried
(MgSO.sub.4). The crude oil was subjected to silica column
chromatography to afford 28 (0.45 g, 66% yield) as a colorless
liquid: R.sub..function.0.28 (60% EtOAc/hexane);
[0104] .sup.1H-NMR (CDCl.sub.3) .delta. 5.72 (m, 2H), 5.52 (m, 2H),
5.13 (septet, J=6.7 Hz, 1H), 4.70 (m, 1H), 4.45-4.25 (m, 2H),
4.20-3.68 (broad m, 8H), 3.45 (m, 1H), 3.28 (m, 1H), 2.60 (m, 1H),
2.08-1.35 (broad m, 15H), 1.28 (d, J=7.2 Hz, 6H), 1.25-0.90 (broad
m, 3H).
I:Isopropyl
[2R(1E,3S),3R(5Z),4S]-7-[Tetrahydro-4-Chloro-2-[3-Cyclohexyl-3-
-Hydroxy-1-Propenyl]-3-Furanyl]-3-Oxa-5-Heptenoate (Compound
VII)
[0105] A solution of the ester 28 (0.2 g, 0.4 mmol) in 5.0 mL of
anhydrous pyridine was cooled to 0.degree. C., and to it
methanesulfonyl chloride (80 mL, 1.04 mmol) was added. The
resulting solution was stirred at 0.degree. C. for 5 min and then
at room temperature for 24 h. The reaction mixture was poured into
50 mL of ether and washed with 4.times.25 mL of a saturated aqueous
CuSO.sub.4 solution and dried (MgSO.sub.4). The crude was purified
by passage through a column of silica to afford 0.21 g (97% yield)
of the mesylate 29 as a pale yellow liquid: R.sub..function.0.30
(60% EtOAc/hexane).
[0106] The mesylate 29 obtained above (0.21 g, 0.39 mmol), and LiCl
(0.17 g, 4.0 mmol) were dissolved in 10 mL of anhydrous DMF and the
resulting solution was heated at 65-75.degree. C. for 24 h. The
reaction was cooled to room temperature, and poured into
ether/water. The layers were separated, the aqueous layer was
extracted with 3.times.25 mL of ether; the organic layers were
combined and washed with 2.times.10 mL water and brine and dried
(Na.sub.2SO.sub.4). Filtration and solvent removal followed by
chromatography of the crude on silica afforded compound VII (51 mg,
32% yield) as a colorless oil: R.sub..function.0.50 (60%
EtOAc/hexane);
[0107] .sup.1H-NMR (CDCl.sub.3) .delta. 5.82-5.60 (broad m, 4H),
5.08 (septet, J=6.7 Hz, 1H), 4.20-3.82 (broad m, 10H), 2.32 (m,
2H), 2.15 (m, 1H), 1.90-1.55 (broad m, 8H), 1.50-0.90 (broad m,
8H), 1.28 (d,J=7.3 Hz, 6H); .sup.13C-NMR(CDCl.sub.3) .delta.
169.92, 135.26, 130.32, 130.19, 127.86, 83.97, 76.57, 74.22, 68.63,
67.69, 66.60, 59.96, 54.73, 43.61, 28.90, 28.48, 27.87, 26.54,
26.16, 26.09, 21.89; MS m/z at 437 for (M+Na).sup.+.
EXAMPLE 4
Synthesis of Isopropyl
[2R(1E,3R),3S(4Z),4R]-7-[Tetrahydro-2-[4-(3-Chlorop-
henoxy)-3-Hydroxy-1-Butenyl]-4-Hydroxy-3-Furanyl]-4-Heptenoate
(VIII)
[0108] Compound VIII may be prepared as described in the following
Scheme 4. 15
A:(3aR,4S,6aR)-4-(Tert-Butyldiphenylsilyloxy)Methylhexahydrofuro[3,4-b]Fur-
an-2-One (30)
[0109] A mixture of alcohol 10 (5.0 g, 31.6 mmol) and imidazole
(4.3 g, 63.2 mmol) was dissolved in 100 mL of anhydrous DMF. To
this solution tert-butyldiphenylsilyl chloride (10.4 g, 38.0 mmol)
was added and the resulting mixture was stirred at room temperature
for 14 h. The solvent was evaporated and the residue was taken up
in 100 mL of EtOAc, washed with water (2.times.50 mL), dilute
aqueous solution of HCl (2.times.50 mL) and brine and dried
(MgSO4). The solvent was evaporated and the crude was purified by
chromatography on silica gel to afford 30 (12.4 g, quantitative
yield) as a white solid: R.sub..function.0.6 (60%
EtOAc/hexanes);
[0110] .sup.1H-NMR (CDCl.sub.3) .delta. 7.65 (m, 4H), 7.42 (m, 6H),
5.10 (m, 1H), 4.25 (dd, J=12, 4 Hz, 1H), 4.05 (dd, J=12, 2 Hz, 1H),
3.85 (m, 1H), 3.75 (m, 2H), 3.00 (m, 1H), 2.82 (dd, J=16, 7 Hz,
1H), 2.45 (dd, J=16, 2 Hz, 1H), 1.05 (s, 9H).
B:Isopropyl
[2S,3S(4Z),4R]-7-[Tetrahydro-2-(Tert-Butyldiphenylsilyloxy)Met-
hyl-4-Hydroxy-3-Furanyl]-4-Heptenoate (33)
[0111] A solution of the lactone 30 (5.7 g, 14.5 mmol) in 150 mL of
anhydrous THF was cooled to -78.degree. C. under an inert
atmosphere, and to it DIBAL-H (14.5 mL, 1.5 M in toluene, 21.7
mmol) was added dropwise. The resulting mixture was stirred at
-78.degree. C. for 1.5 h and was then quenched at the same
temperature by the addition of 5 mL of methanol. The reaction was
warmed to room temperature, an equal volume of a saturated aqueous
solution of potassium sodium tartrate was added to it and the
resulting slurry was stirred at room temperature for 1 h. The
layers were separated, and the aqueous layer was extracted with
3.times.25 mL of EtOAc. The organic layers were combined and washed
with brine and dried (MgSO.sub.4). The solution was filtered and
concentrated and the crude was purified by passage through a short
column of silica gel to afford the intermediate lactol (5.6 g,
quantitative yield) as a colorless oil: R.sub..function.0.5 (60%
EtOAc/hexanes).
[0112] A suspension of (methoxymethyl)triphenylphosphonium chloride
(2.5 g, 7.5 mmol) in 70 mL of dry THF was cooled to 0.degree. C.
under a N.sub.2 atmosphere. To this solution potassium
tert-butoxide (t-BuOK, 9.0 mL, 1.0 M in THF, 9.0 mmol) was added
dropwise and stirring was continued at 0.degree. C. for an
additional 20 min. At this time a solution of the lactol obtained
above (1.0 g, 2.5 mmol) in 30 mL of dry THF was added to it, and
the resulting mixture was stirred at 0.degree. C. for 1.5 h. The
reaction was then worked up by pouring it into 50 mL of a saturated
aqueous solution of KH.sub.2PO.sub.4, the layers were separated and
aqueous layer was extracted with 3.times.25 mL of EtOAc. The
combined organic layers were washed with water and brine and dried
(MgSO.sub.4); solvent removal and chromatography of the crude on
silica afforded the enolether 31 (0.89 g, 83% yield) as a colorless
liquid: R.sub..function.0.6 (60% EtOAc/hexanes).
[0113] A solution containing enolether 31 (2.45 g, 5.7 mmol),
p-toluenesulfonic acid (0.1 g) and water (10 mL) in 150 mL of THF
was heated at reflux for 3 h. The mixture was then cooled to room
temperature and poured into 50 mL of a saturated aqueous solution
of NaHCO.sub.3. The layers were separated and aqueous layer was
extracted with EtOAc. The organic extracts were combined and dried
(MgSO.sub.4) and the crude product was subjected to chromatography
on silica to afford 32 (1.44 g, 60% yield) as a colorless liquid.
This material was used in the next reaction: R.sub..function.0.28
(50% EtOAc/hexanes).
[0114] A suspension of (3-carboxypropyl)triphenylphosphonium
bromide (4.5 g, 10.5 mmol) in 70 mL of dry THF was cooled to
0.degree. C. and to it t-BuOK (21.0 mL, 1.0 M in THF, 21.0 mmol)
was added dropwise. The resulting solution of the ylid was stirred
for 30 min at 0.degree. C. and to it a solution of the lactol 32
(1.44 g, 3.5 mmol) in 30 mL of dry THF was added dropwise over a
period of 10 min. The reaction was allowed to warm to room
temperature gradually, and was stirred at that temperature for 14
h. The mixture was then poured into 50 mL of a saturated aqueous
solution of KH.sub.2PO.sub.4, and extracted with 3.times.25 mL of
EtOAc. The organic extracts were combined and washed with brine and
dried (MgSO.sub.4). Filtration and solvent removal afforded an oily
residue which was used immediately in the subsequent step.
[0115] The crude product from above was dissolved in 40 mL of
acetone and the solution was treated with DBU (12.0 mL, 84 mmol) at
room temperature for 10 min. Isopropyl iodide (7.0 mL, 70 mmol) was
then introduced and the resulting mixture was stirred at room
temperature for 18 h. Solvent was then evaporated and the residue
was dissolved in 50 mL of EtOAc. This solution was washed
sequentially with 3.times.25 mL of a saturated aqueous solution of
KH.sub.2PO.sub.4, 1.times.10 mL of water and brine and dried over
anhydrous MgSO.sub.4. Filtration, solvent removal and
chromatography of the crude on silica gel afforded the desired
isopropyl ester 33 (1.18 g, 65% yield from 32) as a slightly yellow
liquid: R.sub..function.0.2 (30% EtOAc/hexanes);
[0116] .sup.1H-NMR (CDCl.sub.3) .delta. 7.71 (m, 4H), 7.40 (m, 6H),
5.38 (m, 2H), 5.00 (septet, J=6.4 Hz, 1H), 4.38 (m, 1H), 3.65-4.00
(broad m, 5H), 1.90-2.50 (broad m, 7H), 1.55 (m, 2H), 1.23 (d,
J=7.2 Hz, 6H), 1.05 (s, 9H); MS m/z at 547 for (M+Na).sup.+.
C:Isopropyl
[2S,3R(4Z),4R]-7-[Tetrahydro-2-Hydroxymethyl-4-(Tetrahydropyra-
n-2-yl)Oxy-3-Furanyl]-4-Heptenoate (35)
[0117] A solution of the alcohol 33 (1.18 g, 2.3 mmol) and
3,4-dihydro-2H-pyran (0.3 mL, 3.4 mmol) in 50 mL of
CH.sub.2Cl.sub.2 was cooled to 0.degree. C. and to it a catalytic
amount of p-toluenesulfonic acid (10 mg) was added. The resulting
mixture was stirred at 0.degree. C. for 25 min and was then
quenched by the addition of 25 mL of a saturated aqueous solution
of NaHCO.sub.3. The mixture was warmed to room temperature, the
layers were separated and the aqueous layer was extracted with
3.times.25 mL of CH.sub.2Cl.sub.2. The organic layers were combined
and washed with brine and dried (K.sub.2CO.sub.3). The crude
obtained after filtration and solvent removal was purified by
passage through a short plug of silica to afford the intermediate
tetrahydropyranyl ether 34 as colorless liquid: R.sub..function.0.4
(30% EtOAc/hexanes).
[0118] The silyl ether 34 thus obtained was dissolved in 20 mL of
THF and the solution was treated with tetra-n-butylammonium
fluoride (7.0 mL, 1.0 M in THF, 7.0 mmol) at room temperature for 2
h. The reaction mixture was then poured into water and was
extracted with EtOAc (3.times.25 mL). The organic extracts were
combined and dried (MgSO.sub.4), filtered and concentrated. The
crude was subjected to chromatography on silica to afford the
alcohol 35 (0.72 g, 85% yield from 33) as a colorless liquid:
R.sub..function.0.16 (50% EtOAc/hexanes);
[0119] .sup.1H-NMR (d.sub.6-DMSO) .delta. (partial spectrum) 5.36
(m, 2H), 4.87 (septet, J=6.5 Hz, 1H), 4.60 (m, 2H), 1.18 (d, J=7.2
Hz, 6H).
D:Isopropyl [b
2S,3R(4Z),4R]-7-[Tetrahydro-2-Formyl-4-(Tetrahydropyran-2-y-
l)Oxy-3-Furanyl]-4-Heptenoate (36)
[0120] A solution of oxalyl chloride (2.0 mL, 2.0 M in
CH.sub.2Cl.sub.2, 4.0 mmol) in 10 mL of dry CH.sub.2Cl.sub.2 was
cooled to -78.degree. C., and to it a solution of DMSO (0.56 mL,
8.0 mmol) in 5 mL of CH.sub.2Cl.sub.2 was introduced dropwise.
After the mixture was stirred for 3 min at -78.degree. C., a
solution of the substrate 35 (0.72 g, 2.0 mmol) in 25 mL of
CH.sub.2Cl.sub.2 was added to it dropwise. The mixture was stirred
for 15 min, at which time triethylamine (1.7 mL, 12.0 mmol) was
introduced, and stirring was continued for an additional 15 min.
The reaction was gradually warmed to room temperature and then
poured into 50 mL of water. The layers were separated and the water
layer was extracted with 3.times.25 mL of CH.sub.2Cl.sub.2. The
combined organic extracts were washed with water and brine and
dried (MgSO.sub.4). Filtration and solvent removal, followed by
chromatography of the crude on silica afforded the aldehyde 36
(0.69 g, 94% yield) as a pale yellow liquid: R.sub..function.0.3
(50% EtOAc/hexanes);
[0121] .sup.1H-NMR (CDCl.sub.3) .delta. (partial spectrum) 9.66 (d,
J=3 Hz, 1H), 5.37 (m, 2H), 5.0 (septet, J=6.5 Hz, 1H), 1.24 (d,
J=7.2 Hz, 6H).
E:Isopropyl
[2R(1E),3R(4Z),4R]-7-[Tetrahydro-2-[4-(3-Chlorophenoxy)-3-Oxo--
1-Butenyl]-4-(Tetrahydropyran-2-yl)Oxy-3-Furanyl]-4-Heptenoate
(37)
[0122] A mixture of the aldehyde 36 (0.32 g, 0.87 mmol),
dimethyl-3-(3-chlorophenoxy)-2-oxopropylphosphonate (1.0 g, 3.5
mmol) and LiCl (0.15 g, 3.5 mmol) was taken up in 40 mL of dry THF,
and the solution was cooled to 0.degree. C. under a N.sub.2
atmosphere. To this solution, triethylamine (0.5 mL, 3.5 mmol) was
added dropwise, and the resulting slurry was stirred at 0.degree.
C. for 1 h. The reaction was then quenched by pouring it into 50 mL
of a saturated aqueous solution of KH.sub.2PO.sub.4. The organic
layer was separated and the aqueous layer was extracted with
3.times.25 mL of EtOAc. The organic extracts were combined and
washed with water and brine and dried (MgSO.sub.4). The crude
product mixture was subjected to chromatography on silica to afford
the enone 37 (0.34 g, 73% yield) as a pale yellow liquid:
R.sub..function.0.6 (60% EtOAc/hexanes);
[0123] .sup.1H-NMR (CDCl.sub.3) .delta. (partial spectrum) 6.70-
7.20 (broad m, 5H), 6.12 (d, J=16.7 Hz, 1H), 5.36 (m, 2H), 5.0
(septet, J=6.5 Hz, 1H), 4.73 (s, 2H), 1.23 (d, J=7.5 Hz, 6H).
F:Isopropyl
[2R(1E,3RS),3R(4Z),4R]-7-[Tetrahydro-2-[4-(3-Chlorophenoxy)-3--
Hydroxy-1-Butenyl]-4-(Tetrahydropyran-2-yl)Oxy-3-Furanyl]-4-Heptenoate
(38)
[0124] A mixture of the enone 37 (0.34 g, 0.64 mmol) and
CeCl.sub.3.7H.sub.2O (0.47 g, 1.27 mmol) was dissolved in 30 mL of
methanol and the solution was cooled to -5.degree. C. NaBH.sub.4
(47 mg, 1.27 mmol) was added to the solution in small portions over
a period of 3 min. The mixture was stirred for an additional 3 min
and the reaction was quenched at -5.degree. C. by the addition of
10 mL of a saturated aqueous solution of NH.sub.4Cl. The resulting
slurry was warmed to room temperature and partitioned between
CHCl.sub.3 and water. The aqueous layer was extracted with
3.times.25 mL of CHCl.sub.3 and the combined organic extracts were
washed with 2.times.10 mL of water and brine. The organic layer was
dried, filtered and concentrated and the crude was purified by
chromatography on silica to afford the reduction product 38 (0.30
g, 87% yield) as a colorless liquid: R.sub..function.0.24 (50%
EtOAc/hexanes).
G:Isopropyl
[2R(1E,3R),3S(4Z),4R]-7-[Tetrahydro-2-[4-(3-Chlorophenoxy)-3-H-
ydroxy-1-Butenyl]-4-Hydroxy-3-Furanyl]-4-Heptenoate (Compound
VIII)
[0125] The allyl alcohol 38 (0.30 g, 0.55 mmol) was dissolved in a
mixture of 10 mL of methanol and 1.0 mL of water, and the solution
was cooled to 0.degree. C. Approximately 10 drops of 12 N HCl was
added to it dropwise and the mixture was stirred at 0.degree. C.
for 15 min and then at room temperature for 1 h. The reaction was
then quenched by the addition of solid NaHCO.sub.3, and the
suspension was partitioned between CHCl.sub.3/water. The layers
were separated and the aqueous layer was extracted with 3.times.25
mL of CHCl.sub.3. The organic extracts were combined and washed
with water (2.times.10 mL) and brine and dried (Na.sub.2SO.sub.4).
Filtration and solvent removal gave an oil which was subjected to
silica gel chromatography. The two diastereomers were isolated
separately, and the desired compound VIII (61 mg, 25% yield) was
obtained as colorless liquid: R.sub..function.0.15 (60%
EtOAc/hexanes);
[0126] .sup.1H-NMR (CDCl.sub.3) .delta. 7.17 (m, 1H), 6.90 (m, 2H),
6.78 (m, 1H), 5.84 (m, 2H), 5.35 (m, 2H), 5.00 (septet, J=6.4 Hz,
1H), 4.55 (m, 1H), 4.40 (m, 1H), 3.80-4.15 (broad m, 5H), 1.90-2.65
(broad m, 8H), 1.75 (m, 2H), 1.45 (m, 2H), 1.21 (d, J=7.4 Hz, 6H);
.sup.13C-NMR (CDCl.sub.3) .delta. 173.08, 159.19, 134.90, 132.69,
130.68, 130.57, 130.26, 128.07, 121.35, 115.09, 113.04, 82.21,
75.45, 72.62, 71.83, 70.12, 67.94, 50.84, 34.36, 25.78, 24.55,
22.70, 21.89, 21.80; HRMS m/z calculated for
C.sub.24H.sub.33O.sub.6ClNa (M+Na.sup.+) 475.185884, found
475.18588.
EXAMPLE 5
Synthesis of Isopropyl
[2S(3S),3R(5Z),4S]-7-[Tetrahydro-4-Chloro-2-(3-Cycl-
ohexyl-3-Hydroxy-1-Propynyl)-3-Furanyl]-3-Oxa-5-Heptenoate (IX)
[0127] Compound IX may be prepared as described in the following
Scheme 5. 16
Isopropyl
[2S(3S),3R(5Z),4S]-7-[Tetrahydro-4-Chloro-2-(3-Cyclohexyl-3-Hydr-
oxy-1-Propynyl)-3-Furanyl]-3-Oxa-5-Heptenoate (IX)
[0128] The aldehyde 11 is treated with CBr.sub.4 and
triphenylphosphine to form the dibromoolefin 39. Lactone 39 is
reduced to the lactol with diisobutylaluminum hydride (DIBAL-H) and
this intermediate is reacted with trimethyl orthoformate in the
presence of a catalytic amount of p-toluenesulfonic acid to afford
the methyl glycoside 40. Treatment of compound 40 with n-BuLi
followed by cyclohexanecarboxaldehyde yields the propargyl alcohol
intermediate, which is reacted with tert-butyldiphenylsilyl
chloride in the presence of base to afford the silyl ether 41. The
methylglycoside moiety is removed by treatment of 41 with
p-toluenesulfonic acid in refluxing THF/water, and the intermediate
lactol is further reduced with DIBAL-H to the diol; treatment of
the intermediate diol with chlorotriethylsilane (3 equivalents)
under standard conditions, followed by separation of the
diastereomers by column chromatography on silica affords the fully
protected compound 42. Swern oxidation of 42 affords the aldehyde
43, which is homologated with
bis(2,2,2-trifluoroethyl)(methoxycarbonylmethyl)phosphonate in the
presence of KHMDS to give the diastereomeric mixture of crotonates
44. The ester 44 is reduced with DIBAL-H to the diastereomeric
mixture of allylic alcohols 45 which is selectively deprotected
(AcOH, H.sub.2O, THF, room temperature), and the intermediate diol
diastereomers are separated by column chromatography to afford the
allylic alcohol 46. The diol 46 is alkylated with isopropyl
bromoacetate under phase-transfer conditions (toluene, H.sub.2O,
NaOH, (n-Bu).sub.4NHSO.sub.4, 0.degree. C.) to give the ester 47,
which is reacted with methansulfonyl chloride in the presence of
pyridine to afford the mesylate 48. Treatment of the mesylate 48
with LiCl in DMF at 80.degree. C. gives the chlorinated compound 49
which when reacted with tetra-n-butylammonium fluoride affords
compound IX.
[0129] The substituted tetrahydrofurans of the present invention
may be formulated in various pharmaceutical compositions for
administering to humans and other mammals as a treatment of
glaucoma or ocular hypertension. As used herein, the term
"pharmaceutically effective amount" refers to that amount of a
compound of the present invention which lowers IOP when
administered to a patient, especially a mammal. The preferred route
of administration is topical. The compounds of the present
invention can be administered as solutions, suspensions, or
emulsions (dispersions) in an ophthalmically acceptable vehicle. As
used herein, the term "ophthalmically acceptable vehicle" refers to
any substance or combination of substances which are non-reactive
with the compounds and suitable for administration to a patient.
Solubilizers and stabilizers are deemed to be non-reactive.
Preferred are aqueous vehicles suitable for topical application to
the patient's eyes.
[0130] In forming compositions for topical administration, the
compounds of the present invention are generally formulated as
between about 0.00003 to about 0.5 percent by weight (wt %)
solutions in water at a pH between about 4.5 to about 8.0,
preferably between about 5.0 and about 7.5. The compounds are
preferably formulated as between about 0.0005 to about 0.03 wt %
and, most preferably, between about 0.001 and about 0.01 wt %.
While the precise regimen is left to the discretion of the
clinician, it is recommended that the resulting solution be
topically applied by placing one drop in each eye one or two times
a day.
[0131] Other ingredients which may be desirable to use in the
ophthalmic preparations of the present invention include
preservatives, co-solvents, and viscosity building agents.
[0132] Antimicrobial Preservatives:
[0133] Ophthalmic products are typically packaged in multidose
form. Preservatives are thus required to prevent microbial
contamination during use. Suitable preservatives include:
benzalkonium chloride, thimerosal, chlorobutanol, methyl paraben,
propyl paraben, phenylethyl alcohol, edetate disodium, sorbic acid,
Onamer M, or other agents known to those skilled in the art. Such
preservatives are typically employed at a level between about
0.001% and about 1.0% by weight.
[0134] Co-Solvents:
[0135] Prostaglandins, and particularly ester derivatives,
typically have limited solubility in water and therefore may
require a surfactant or other appropriate co-solvent in the
composition. Such co-solvents include: Polysorbate 20, 60 and 80;
Pluronic F-68, F-84 and P-103; CREMOPHORE.RTM. EL (polyoxyl 35
castor oil); cyclodextrin; or other agents known to those skilled
in the art. Such co-solvents are typically employed at a level
between about 0.01% and about 2% by weight.
[0136] Viscosity Agents:
[0137] Viscosity greater than that of simple aqueous solutions may
be desirable to increase ocular absorption of the active compound,
to decrease variability in dispensing the formulations, to decrease
physical separation of components of a suspension or emulsion of
formulation and/or otherwise to improve the ophthalmic formulation.
Such viscosity building agents include, for example, polyvinyl
alcohol, polyvinyl pyrrolidone, methyl cellulose, hydroxy propyl
methylcellulose, hydroxyethyl cellulose, carboxymethyl cellulose,
hydroxy propyl cellulose, chondroitin sulfate and salts thereof,
hyaluronic acid and salts thereof, and other agents known to those
skilled in the art. Such agents are typically employed at a level
between about 0.01% and about 2% by weight.
[0138] Preferred formulations of substituted tetrahydrofurans of
the present invention include the following Examples 6-8:
EXAMPLE 6
[0139]
2 Ingredient Amount (wt %) Compound VI 0.01 Monobasic sodium
phosphate 0.05 Dibasic sodium phosphate 0.15 (anhydrous) Sodium
chloride 0.75 Disodium EDTA (Edetate disodium) 0.05 Cremophor .RTM.
EL 0.1 Benzalkonium chloride 0.01 HCl and/or NaOH q.s. pH 7.3-7.4
Purified water q.s. 100%
EXAMPLE 7
[0140]
3 Ingredient Amount (wt %) Compound VII 0.003 Sodium acetate
(trihydrate) 0.07 Mannitol 4.3 Disodium EDTA (Edetate disodium) 0.1
Cremophor .RTM. EL 0.5 Benzalkonium chloride 0.01 HCl and/or NaOH
q.s. pH 5.0 Purified water q.s. 100%
EXAMPLE 8
[0141]
4 Ingredient Amount (wt %) Compound VIII 0.05 Phosphate Buffered
Saline 1.0 Hydroxypropyl-.beta.-cyclodextrin 4.0 Purified water
q.s. 100%
[0142] The invention has been described by reference to certain
preferred embodiments; however, it should be understood that it may
be embodied in other specific forms or variations thereof without
departing from its spirit or essential characteristics. The
embodiments described above are therefore considered to be
illustrative in all respects and not restrictive, the scope of the
invention being indicated by the appended claims rather than by the
foregoing description.
* * * * *